David Ledbetter is chief clinical officer of Dascena, a personalized medicine company.
David Ledbetter
Chief clinical officer
Dascena
From this contributor
There are no autism-specific genes, just brain genes
There is not yet a single example of a gene that, when mutated, increases the likelihood of autism but not of other neurodevelopmental conditions, including intellectual disability.
There are no autism-specific genes, just brain genes
By
David Ledbetter, Scott Myers
23 March 2021 | 5 min read
Developmental disorders should be viewed as continuum
Intellectual disability, autism, epilepsy and schizophrenia should be considered part of a spectrum of developmental brain dysfunction, says David Ledbetter.
Developmental disorders should be viewed as continuum
By
David Ledbetter
6 May 2013 | 3 min read
Explore more from The Transmitter
Measuring plastic in the brain: Improving, but incomplete
Meanwhile, researchers are publishing papers without “sufficient quality control,” says analytical chemist Dušan Materić.
Measuring plastic in the brain: Improving, but incomplete
Meanwhile, researchers are publishing papers without “sufficient quality control,” says analytical chemist Dušan Materić.
By
Amber Dance
18 September 2026 | 9 min read
Incredible shrinking grant deadlines at the BRAIN Initiative
“A month is crazy,” says one former recipient, referring to a new funding opportunity’s timeline.
Incredible shrinking grant deadlines at the BRAIN Initiative
“A month is crazy,” says one former recipient, referring to a new funding opportunity’s timeline.
By
Brendan Borrell
17 September 2026 | 4 min read
Sylvia Fogel, reshaping U.S. autism research strategy
In a wide-ranging and provocative interview, the chair of the federal Interagency Autism Coordinating Committee shares her views on vaccines, regression, neuroimmune conditions and more.
Sylvia Fogel, reshaping U.S. autism research strategy
In a wide-ranging and provocative interview, the chair of the federal Interagency Autism Coordinating Committee shares her views on vaccines, regression, neuroimmune conditions and more.
By
Brady Huggett
17 September 2026 | 1 min read